Prollenium Unveils New Leadership Structure
In a significant leadership transition aimed at fostering continued growth and innovation, Prollenium Medical Technologies (“Prollenium” or “the Company”) has announced that Ario Khoshbin, the Company’s longtime Chief Executive Officer, will be stepping down from his current role. Khoshbin will transition to focus on his position as a member of the Company’s Board of Directors. Importantly, he remains a key stakeholder in Prollenium, continuing to hold a significant ownership share in the enterprise.
Founded with a vision to lead in the development and manufacturing of advanced aesthetic solutions, Prollenium has steadily built a reputation for excellence in aesthetics, particularly through its flagship dermal filler products. Over the years, the Company has gained recognition for its dedication to scientific research, manufacturing integrity, and regulatory compliance—elements that have formed the foundation of its global reputation.
Ario Khoshbin has played a central role in guiding Prollenium’s growth since its inception. Under his leadership, the company has expanded its product pipeline, enhanced its manufacturing infrastructure, and grown its market presence beyond North America to international markets. Khoshbin’s tenure as CEO has been characterized by strategic expansion and a relentless focus on innovation and customer satisfaction. His decision to step down marks the end of an era, but also a new beginning for Prollenium as it moves into its next phase of growth.
“Welcoming a CEO with new expertise and perspective will allow Prollenium to continue to achieve its potential as one of the world’s leading global developers and manufacturers of aesthetic products,” said Justin Bateman, Chair of Prollenium’s Board of Directors. “We appreciate and thank Ario for the significant contributions that he has made throughout his long and successful tenure as CEO. We will continue to work alongside the board and leadership team to scale Prollenium’s platform and convert its robust product pipeline into an expanding suite of products to serve both existing and new customers in North America and internationally.”
Khoshbin’s transition to a Board role enables him to stay engaged in the Company’s overarching strategic direction, while paving the way for fresh leadership to guide the company through its next stage of transformation. The Company emphasized that this move is part of a thoughtful and proactive succession plan aimed at positioning Prollenium for long-term global success.
As part of this leadership transition, Prollenium has appointed Walter Geiger as Acting Chief Executive Officer, effective immediately. The decision was made while the Board of Directors undertakes a formal search for a permanent CEO. Geiger brings with him a strong pedigree in the healthcare and consumer sectors, with over three decades of experience leading major international brands and managing high-growth business units across multiple regions.
Walter Geiger’s professional background is extensive and particularly well-suited to Prollenium’s next phase. Most recently, he served as Chairman of the Board for Cellese Regenerative Therapeutics, a company known for its cutting-edge work in regenerative medicine. Prior to that, Geiger was President of the Global Consumer Business Unit at Galderma, a global leader in dermatology and aesthetic medicine. In this capacity, he oversaw strategic operations and product expansion initiatives that spanned key international markets.
Earlier in his career, Geiger held a number of senior leadership roles at prominent global corporations such as Procter & Gamble and Johnson & Johnson. At these organizations, he was responsible for leading business units with profit-and-loss responsibility across North America, Europe, and Asia. His experience managing complex international operations, coupled with his deep understanding of both consumer behavior and regulatory landscapes, positions him as an ideal steward for Prollenium during this transitional period.
Commenting on his new role, Geiger stated, “Prollenium’s success has been fueled by its commitment to product development, innovative research, and regulatory and manufacturing excellence. I look forward to working with the Board and management team to ensure we continue to execute on its strategic priorities as we begin the next exciting chapter in Prollenium’s story.”
Geiger’s appointment is being viewed as a strategic move by the Board to maintain operational momentum and ensure a seamless leadership transition. His proven track record of scaling organizations and commercializing scientific innovations will be invaluable as Prollenium prepares to bring new products to market and expand its geographic reach.
Prollenium’s Board emphasized that the search for a permanent CEO is already underway. The goal is to identify a candidate who aligns with the company’s long-term vision and has the capability to lead it through the next decade of innovation and expansion. During this interim period, Geiger will work closely with the existing leadership team to maintain business continuity, drive growth initiatives, and ensure that the company remains focused on its mission to deliver high-quality aesthetic solutions that improve patient outcomes.
The Company remains committed to its core values of innovation, quality, and customer-centricity. It continues to invest heavily in R&D, regulatory compliance, and manufacturing infrastructure to ensure its products meet the highest industry standards. With several new products in late-stage development, Prollenium is preparing to enter new segments within the aesthetic and medical dermatology space.
Industry analysts view this leadership change as a positive inflection point for Prollenium. By bringing in a seasoned executive with deep experience in both operational management and scientific innovation, the Company is reinforcing its commitment to growth, modernization, and international market expansion. The ongoing evolution of Prollenium’s leadership team is expected to further bolster its position as a key player in the global aesthetics market.
Ario Khoshbin’s continued involvement as a board member and shareholder will provide continuity and strategic oversight, ensuring that the Company remains true to its founding principles while embracing new opportunities. His legacy as a visionary founder and builder of the Prollenium brand will continue to influence the organization’s culture and strategic priorities for years to come.
As Prollenium embarks on this new chapter, it does so from a position of strength—armed with a robust product pipeline, a skilled leadership team, and an unwavering dedication to quality and innovation. Stakeholders, customers, and industry partners alike can look forward to what promises to be a dynamic and growth-oriented future for the Company.
